Table 2 Results of base case analysis
Vaborem | BAT | Difference | Percentage change | |
|---|---|---|---|---|
Costs (€) | ||||
Total Costs | 29,750.85 | 26,202.28 | 3548.57 | 13.5% |
Pharmacological treatment | 2301.49 | 1485.23 | 816.26 | 55.0% |
Admission | 3048.04 | 3048.04 | 0.00 | 0.0% |
Therapeutic failure | 1841.64 | 3324.40 | − 1482.76 | −44.6% |
Chronic RRT | 129.49 | 873.10 | − 743.61 | − 85.2% |
Long-term care | 22,430.18 | 17,471.51 | 4958.68 | 28.4% |
Clinical Effectiveness | ||||
Total QALY | 1.786 | 1.403 | 0.384 | 27.4% |
Nephrotoxicity-free hospitalisation | 0.033 | 0.031 | 0.002 | 7.2% |
Hospitalisation with nephrotoxicity | 0.002 | 0.013 | −0.012 | − 88.3% |
Acute RRT | 0.000 | 0.002 | −0.002 | −85.2% |
Chronic RRT (after 90 days) | 0.002 | 0.013 | −0.011 | −85.2% |
After Hospital discharge | 1.749 | 1.343 | 0.406 | 30.3% |
Total LYs | 2.253 | 1.778 | 0.475 | 26.7% |